Risk for hospitalization after surgery or radiation therapy for localized prostate cancer

According to a newly published article in BJU International, there was little to no major difference in the risks for hospitalization within 1 year after first-line treatment among relatively healthy, Medicare-eligible men with localized prostate cancer treated by either radical surgery or radiation therapy. … READ MORE …

Adverse events of primary, intensity-modulated radiation therapy (IMRT)

In a recent commentary, the Sitemaster mentioned some common adverse effects of radical prostatectomy, some of which (e.g., perceived penile shrinkage, climacturia) are seldom mentioned by urologists to prospective patients, and are not routinely included in standardized quality-of-life questionnaires. … READ MORE …

Understanding the range of risks associated with prostate cancer surgery today

It would certainly be difficult (and arguably impossible) for us to provide a newly diagnosed prostate cancer patient with a  comprehensive list of all the possible side effects and complications that might be associated with every type of first-line treatment for prostate cancer. However, … READ MORE …

Side effects of salvage radiation — difficult to draw conclusions based on database analyses

Two analyses of Italian and US databases have investigated whether delaying initiation of radiation therapy could diminish the side effects of radiation after prostatectomy. The conventional wisdom is that waiting longer allows the newly cut tissues more time to heal completely before the onslaught of radiation. … READ MORE …

One more reason to cut out the cigarettes

Surgeons already don’t like to operate on smokers. They don’t do as well during and after surgery as non-smokers, not least because smokers can have problems with anesthesia. Now come data suggesting that smoking during radiation therapy is a pretty lousy idea too. … READ MORE …

5-year cumulative incidence of complications after surgery or radiation therapy

A new report just published in Lancet Oncology provides data on complications other than incontinence and erectile dysfunction (ED) after surgical or radiotherapeutic treatment of prostate cancer within 5 years of the initial treatment. … READ MORE …

Follow-up to earlier commentary on the Michigan Prostate Cancer Survivor study

Late last week we commented briefly on a paper (by Darwish-Yassine et al.) entitled “Evaluating long-term patient centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study.” … READ MORE …

Risks associated with implantation of “fiducial markers” before radiation therapy

It is becoming commonplace for men who are going to get external beam radiotherapy to treat their prostate cancer to have some form of “fiducial marker” (often tiny gold rods or balls) inserted into their prostates under transrectal ultrasound guidance to help ensure that the radiotherapy can be administered with the greatest possible accuracy. … READ MORE …

GTx forced to stop development of Capesaris (GTx-758)

The US Food & Drug Administration (FDA) has advised GTx to stop development of GTx-758 (also known as Capesaris), its oral drug intended for the treatment of men with advanced prostate cancer, after it became apparent that there was an increase in risk for blood clots in men taking active drug compared to those being treated with a placebo. … READ MORE …

Korean study says that HIFU “does not provide effective oncologic outcomes”

A new paper by clinical researchers in Korea has concluded that treatment with high-intensity focused ultrasound (HIFU) “does not provide effective oncologic outcomes even in low risk patients with prostate cancer as well as in the intermediate or high risk groups,” but does have a low associated incidence of treatment complications. … READ MORE …

Brachytherapy: is it really “better” as a first-line treatment for low- and intermediate-risk prostate cancer?

An analysis of data on treatment of nearly 137,500 men treated for prostate cancer between 1991 and 2007 has suggested that permanent seed brachytherapy may be safer, less costly, and at least as effective as any other widely available form of first-line therapy for men with low- and intermediate-risk prostate cancer. … READ MORE …

New data on risks of prostate biopsy and prostate cancer diagnosis, follow-up

According to a new study among Medicare beneficiaries in the USA, researchers have found that 6.9 percent of men having a prostate biopsy are hospitalized within 30 days of the biopsy compared to 2.7 percent of a control group of men who did not have a prostate biopsy. … READ MORE …

Soy isoflavones and radiation therapy: a pilot study

Soy isoflavones are known to have antioxidant and anti-inflammatory activities and to sensitize prostate cancer cells to radiation therapy. … READ MORE …

Acute and late radiation toxicities of proton beam radiation therapy

Over the years there have been almost no publications addressing the complications of proton beam radiation therapy (PBRT) among well-defined series of prostate cancer patients. With the number of PBRT centers now growing fast, good data on the side effects of PBRT are an urgent priority. … READ MORE …

New data on the 5-year complications of radical prostatectomy

The complex and common series of significant short- and long-term complications of radical prostatectomy (RP) — whether conducted with or without the assistance of a robot — are often not well understood by patients when they elect this form of treatment for localized prostate cancer. … READ MORE …